Interim FDG-PET Imaging in Lymphoma

被引:24
|
作者
Gallamini, Andrea [1 ]
Zwarthoed, Colette [2 ]
机构
[1] A Lacassagne Canc Ctr, Res Innovat & Stat Dept, Nice, France
[2] A Lacassagne Canc Ctr, Nucl Med Dept, Nice, France
关键词
POSITRON-EMISSION-TOMOGRAPHY; B-CELL LYMPHOMA; STAGE HODGKINS LYMPHOMA; PROGRESSION-FREE SURVIVAL; PERIPHERAL T-CELL; EARLY F-18-FDG PET; RESPONSE ASSESSMENT; PROGNOSTIC VALUE; OPEN-LABEL; INTERPRETATION CRITERIA;
D O I
10.1053/j.semnuclmed.2017.09.002
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In the present article, the authors reviewed the rationale of FDG-PET/CT performed at an interim time point during therapy (iPET), focusing on the transition from standard, anatomical assessment of tumor shrinkage with CT to document a chemotherapy response, to the use of functional imaging with PET to assess chemosensitivity of the individual tumor. The prognostic or predictive role of iPET in different lymphoma subsets has been reviewed, with particular emphasis on early and advanced-stage Hodgkin lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, extranodal natural killer/T-cell lymphoma, and primary mediastinal B-cell lymphoma. A large body of evidence exists in most lymphoma subtypes stressing the role of iPET for early chemotherapy response during first-line chemotherapy treatment, but an increased number of reports have recently been published focusing on the role of iPET in relapsed or refractory lymphoma to predict treatment outcome. Varying patterns of FDG uptake was observed across various lymphoma entities; hence, interpretation of FDG-PET scans should be in the context of the tumor architecture and the prevalence of cellular population, in particular, neoplastic vs non-neoplastic inflammatory cells present in tissue microenvironment. In the second part of the article, the authors reviewed the iPET response adapted clinical trials and the clinical benefits of this strategy compared to standard non PET adapted therapy. In particular, the authors extrapolated the reproducibility of FDG-PET image interpretation and the feasibility of a timely treatment adaptation based on FDG-PET results in daily clinical practice. This is essential for the reader, as the iPET-adapted strategy has become the standard of care in both early- and advanced-stage Hodgkin lymphoma, and, in the future, probably this strategy will be expanded to primary mediastinal B-cell lymphoma, follicular lymphoma, and peripheral T-cell lymphoma. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:17 / 27
页数:11
相关论文
共 50 条
  • [1] Interim FDG-PET/CT for Response Assessment of Lymphoma
    Zeman, Merissa N.
    Akin, Esma A.
    Merryman, Reid W.
    Jacene, Heather A.
    SEMINARS IN NUCLEAR MEDICINE, 2023, 53 (03) : 371 - 388
  • [2] Interim FDG-PET in lymphoma, a questionable practice in hematology
    Adams, Hugo J. A.
    Kwee, Thomas C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (12) : 2014 - 2017
  • [3] An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma
    Adams, Hugo J. A.
    Kwee, Thomas C.
    SEMINARS IN ONCOLOGY, 2017, 44 (06) : 404 - 419
  • [4] qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma
    Hasenclever, Dirk
    Kurch, Lars
    Mauz-Koerholz, Christine
    Elsner, Andreas
    Georgi, Thomas
    Wallace, Hamish
    Landman-Parker, Judith
    Moryl-Bujakowska, Angelina
    Cepelova, Michaela
    Karlen, Jonas
    Alvarez Fernandez-Teijeiro, Ana
    Attarbaschi, Andishe
    Fossa, Alexander
    Pears, Jane
    Hraskova, Andrea
    Bergstraesser, Eva
    Beishuizen, Auke
    Uyttebroeck, Anne
    Schomerus, Eckhard
    Sabri, Osama
    Koerholz, Dieter
    Kluge, Regine
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (07) : 1301 - 1308
  • [5] Interim FDG-PET/CT in Hodgkin lymphoma: what are we actually looking at?
    Adams, Hugo J. A.
    Kwee, Thomas C.
    ACTA ONCOLOGICA, 2018, 57 (08) : 1128 - 1130
  • [6] Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?
    Gallamini, Andrea
    Kostakoglu, Lale
    BLOOD, 2012, 120 (25) : 4913 - 4920
  • [7] Impact of FDG-PET/CT in the management of lymphoma
    Baba, Shingo
    Abe, Koichiro
    Isoda, Takuro
    Maruoka, Yasuhiro
    Sasaki, Masayuki
    Honda, Hiroshi
    ANNALS OF NUCLEAR MEDICINE, 2011, 25 (10) : 701 - 716
  • [8] FDG PET/CT imaging as a biomarker in lymphoma
    Meignan, Michel
    Itti, Emmanuel
    Gallamini, Andrea
    Younes, Anas
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (04) : 623 - 633
  • [9] FDG-PET/CT in Lymphoma: Where Do We Go Now?
    Al Tabaa, Yassine
    Bailly, Clement
    Kanoun, Salim
    CANCERS, 2021, 13 (20)
  • [10] The role of FDG-PET scans in the evaluation of lymphoma in 2012
    Bodet-Milin, C.
    Eugene, T.
    Gastinne, T.
    Bailly, C.
    Le Gouill, S.
    Dupas, B.
    Kraeber-Bodere, F.
    JOURNAL DE RADIOLOGIE DIAGNOSTIQUE ET INTERVENTIONNELLE, 2013, 94 (02) : 164 - 174